Citigroup’s BioXcel Therapeutics BTAI Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Hold |
0
| – | -$2 | – | 4953 |
|
|
2024
Q3 | – | Sell |
-3,486
| Closed | -$71.4K | – | 4814 |
|
|
2024
Q2 | $71.4K | Buy |
3,486
+3,266
| +1,485% | +$66.9K | ﹤0.01% | 3658 |
|
|
2024
Q1 | $9.91K | Buy |
220
+39
| +22% | +$1.76K | ﹤0.01% | 4441 |
|
|
2023
Q4 | $8.53K | Sell |
181
-1,340
| -88% | -$63.1K | ﹤0.01% | 4466 |
|
|
2023
Q3 | $61.6K | Sell |
1,521
-2,233
| -59% | -$90.4K | ﹤0.01% | 3384 |
|
|
2023
Q2 | $400K | Sell |
3,754
-3,682
| -50% | -$392K | ﹤0.01% | 2881 |
|
|
2023
Q1 | $2.22M | Buy |
7,436
+7,397
| +18,967% | +$2.21M | ﹤0.01% | 1477 |
|
|
2022
Q4 | $13.3K | Sell |
39
-9
| -19% | -$3.07K | ﹤0.01% | 4038 |
|
|
2022
Q3 | $9K | Sell |
48
-67
| -58% | -$12.6K | ﹤0.01% | 4271 |
|
|
2022
Q2 | $24K | Sell |
115
-845
| -88% | -$176K | ﹤0.01% | 4191 |
|
|
2022
Q1 | $321K | Sell |
960
-3,887
| -80% | -$1.3M | ﹤0.01% | 3126 |
|
|
2021
Q4 | $1.58M | Buy |
4,847
+2,387
| +97% | +$777K | ﹤0.01% | 2146 |
|
|
2021
Q3 | $1.2M | Sell |
2,460
-4,066
| -62% | -$1.98M | ﹤0.01% | 2272 |
|
|
2021
Q2 | $3.03M | Buy |
6,526
+1,080
| +20% | +$502K | ﹤0.01% | 1789 |
|
|
2021
Q1 | $3.76M | Buy |
5,446
+5,266
| +2,926% | +$3.64M | ﹤0.01% | 1531 |
|
|
2020
Q4 | $133K | Buy |
180
+87
| +94% | +$64.3K | ﹤0.01% | 3488 |
|
|
2020
Q3 | $65K | Sell |
93
-918
| -91% | -$642K | ﹤0.01% | 3350 |
|
|
2020
Q2 | $857K | Buy |
1,011
+881
| +678% | +$747K | ﹤0.01% | 2209 |
|
|
2020
Q1 | $46K | Buy |
130
+43
| +49% | +$15.2K | ﹤0.01% | 3832 |
|
|
2019
Q4 | $20K | Buy |
87
+68
| +358% | +$15.6K | ﹤0.01% | 4487 |
|
|
2019
Q3 | $2K | Sell |
19
-87
| -82% | -$9.16K | ﹤0.01% | 4945 |
|
|
2019
Q2 | $18K | Buy |
106
+6
| +6% | +$1.02K | ﹤0.01% | 4604 |
|
|
2019
Q1 | $16K | Buy |
+100
| New | +$16K | ﹤0.01% | 4599 |
|